Exelixis
EXEL
$56.89
+4.12%
Exelixis Inc is a biopharmaceutical company focused on discovering, developing, and commercializing cancer treatments, with its lead molecule cabozantinib marketed as Cometriq for medullary thyroid cancer and Cabometyx for kidney and liver cancers. The company holds a strong position in the oncology space, leveraging its expertise in targeted therapies and partnerships, notably with Roche for Cotellic. Currently, the investor narrative centers on the company's robust revenue growth driven by Cabometyx, its expanding pipeline, and its ability to sustain profitability while navigating competitive pressures in the immuno-oncology landscape. Recent attention has also been drawn to the broader sector's volatility, as seen in Merck's clinical setback, which underscores the inherent risks in cancer drug development.…
EXEL
Exelixis
$56.89
Related headlines
Investment Opinion: Should I buy EXEL Today?
Based on the analysis, EXEL is rated a Buy. The company's strong revenue growth, high margins, and undervalued PEG ratio of 0.25 support a positive outlook, despite the average analyst target being slightly below the current price. The consensus recommendation is 'buy' with a mean score of 2.4, and the high target of $66 implies 21% upside, which justifies a Buy rating for investors with a medium-term horizon.
Sign up to view all
EXEL 12-Month Price Forecast
The AI assessment is bullish with medium confidence. Exelixis's fundamentals are strong, with consistent revenue growth, high margins, and a low valuation relative to growth. The main uncertainty lies in pipeline execution and competitive dynamics, which could impact the stock's trajectory. If the company continues to deliver on its commercial strategy and pipeline milestones, the stock has upside potential. However, a downgrade to neutral would occur if revenue growth slows below 5% or if a major pipeline failure occurs.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Exelixis's 12-month outlook, with a consensus price target around $53.00 and implied upside of -6.8% versus the current price.
Average Target
$53.00
0 analysts
Implied Upside
-6.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$41 - $66
Analyst target range
Exelixis is covered by 17 analysts, with a consensus recommendation of 'buy' and a mean recommendation score of 2.4 (where 1 is strong buy and 5 is sell). The average target price is $53.00, which is slightly below the current price of $54.45, implying a -2.7% downside. The distribution includes 10 buy ratings, 6 hold ratings, and 1 sell rating, indicating a generally positive but cautious sentiment. The high target of $66.00 suggests significant upside potential, while the low target of $41.00 reflects downside risks. The wide range between high and low targets indicates uncertainty about the company's future performance, likely due to competitive dynamics and pipeline execution risks.
Bulls vs Bears: EXEL Investment Factors
Exelixis presents a compelling bull case with strong revenue growth, high margins, and a clean balance sheet, but the stock is trading near its 52-week high with limited upside to the average analyst target. The bear case centers on concentration risk and pipeline uncertainty, which are common in biotech. Currently, the bull case has stronger evidence given the PEG ratio of 0.25 and consistent financial performance, but the key tension is whether the market will re-rate the stock higher as growth continues or if competitive pressures will cap upside. The resolution of this tension will determine whether the stock breaks out above $57.57 or consolidates.
Bullish
- Strong revenue growth: Q1 2026 revenue grew 9.97% YoY to $610.8M, with product sales up to $555.0M from $536.3M. This marks the fourth consecutive quarter of sequential revenue growth, indicating accelerating commercial momentum for Cabometyx.
- Undervalued on PEG ratio: The PEG ratio of 0.25x is well below the typical threshold of 1, suggesting the stock is undervalued relative to its growth prospects. With a forward PE of 13.1x and expected EPS growth, the market is pricing in modest growth despite strong fundamentals.
- High profitability and margins: Gross margin is 96.4% (TTM), and operating margin is 37.6%, reflecting a highly efficient business model. Net margin of 33.7% demonstrates strong conversion of revenue to profit, supported by a low cost structure.
- Robust balance sheet: Debt-to-equity is only 0.08, and the current ratio is 3.56, indicating ample liquidity and minimal financial risk. This provides flexibility for pipeline investment and potential strategic moves.
Bearish
- Limited upside to average target: The average analyst target of $53.00 is 2.7% below the current price of $54.45, suggesting the stock is fairly valued or slightly overvalued. This limits near-term upside potential for new investors.
- High short interest: Short ratio of 10.74 indicates significant bearish positioning, which could lead to volatility. High short interest may reflect concerns about competitive pressures or pipeline execution.
- Dependence on Cabometyx: Revenue is heavily concentrated in Cabometyx, which accounts for the majority of product sales. Any setback in this franchise, such as competition or pricing pressure, would materially impact financials.
- Pipeline execution risks: The biotech sector is inherently risky, as highlighted by Merck's recent clinical setback. Exelixis's pipeline is still early-stage, and any failures could undermine growth expectations.
EXEL Technical Analysis
Exelixis has demonstrated a sustained uptrend over the past year, with the stock price appreciating 43.67% over the 1-year period. The current price of $54.45 sits near the upper end of its 52-week range, at approximately 94.6% of the range (calculated as (54.45 - 33.76) / (57.57 - 33.76) = 0.946). This positioning near the highs indicates strong momentum and investor confidence, though it also raises the risk of overextension and potential profit-taking.
Beta
0.42
0.42x market volatility
Max Drawdown
-22.2%
Largest decline past year
52-Week Range
$34-$58
Price range past year
Annual Return
+52.0%
Cumulative gain past year
| Period | EXEL Return | S&P 500 |
|---|---|---|
| 1m | +7.3% | +2.0% |
| 3m | +10.3% | +1.0% |
| 6m | +37.8% | +11.8% |
| 1y | +52.0% | +18.1% |
| ytd | +30.5% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EXEL Fundamental Analysis
Exelixis has shown consistent revenue growth, with the most recent quarter (Q1 2026) reporting revenue of $610.8 million, a 9.97% year-over-year increase. This growth is driven primarily by product sales, which contributed $555.0 million in Q1 2026, up from $536.3 million in Q1 2025. The company's revenue trajectory has been steadily climbing, with quarterly revenues increasing from $555.4 million in Q1 2025 to $610.8 million in Q1 2026, indicating acceleration. The collaboration and license revenues added $112.8 million, providing diversification. This growth is supported by strong demand for Cabometyx and the company's expanding commercial footprint.
Quarterly Revenue
$610812000.0B
2026-04
Revenue YoY Growth
+10.0%
YoY Comparison
Gross Margin
96.7%
Latest Quarter
Free Cash Flow
$916414000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EXEL Overvalued?
Given Exelixis's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 15.13x, while the forward PE is 13.10x, indicating that the market expects earnings growth. The gap between trailing and forward PE suggests an anticipated increase in earnings per share, which is consistent with the company's revenue growth and margin expansion. The PEG ratio of 0.25x further supports the view that the stock is undervalued relative to its growth prospects, as a PEG below 1 typically indicates undervaluation.
PE
15.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 7x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are moderate. Exelixis has a debt-to-equity ratio of 0.08, indicating minimal leverage, and a current ratio of 3.56, providing ample liquidity. However, the company's reliance on Cabometyx for the majority of revenue creates concentration risk; any decline in sales would directly impact profitability. The net margin of 33.7% is robust, but the company's operating expenses, particularly R&D at $199.9M in Q1 2026, are substantial and could pressure margins if revenue growth slows. Free cash flow of $916M TTM is strong, but the company's payout ratio is 0%, meaning no dividend cushion for investors.